Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America
- PMID: 30296479
- PMCID: PMC6445749
- DOI: 10.1016/j.bbmt.2018.09.040
Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America
Abstract
Understanding the socioeconomic impact of chronic graft-versus-host disease (GVHD) on affected patients is essential to help improve their overall well-being. Using data from the Chronic GVHD Consortium, we describe the insurance, employment, and financial challenges faced by these patients and the factors associated with the ability to work/attend school and associated financial burdens. A 15-item cross-sectional questionnaire designed to measure financial concerns, income, employment, and insurance was completed by 190 patients (response rate, 68%; 10 centers) enrolled on a multicenter Chronic GVHD Consortium Response Measures Validation Study. Multivariable logistic regression models examined the factors associated with financial burden and ability to work/attend school. The median age of respondents was 56years, and 87% of the patients were white. A higher proportion of nonrespondents had lower income before hematopoietic cell transplantation and less than a college degree. All but 1 patient had insurance, 34% had faced delayed/denied insurance coverage for chronic GVHD treatments, and 66% reported a financial burden. Patients with a financial burden had greater depression/anxiety and difficulty sleeping. Nonwhite race, lower mental functioning, and lower activity score were associated with a greater likelihood of financial burden. Younger age, early risk disease, and higher mental functioning were associated with a greater likelihood of being able to work/attend school. In this multicenter cohort of patients with chronic GVHD, significant negative effects on finances were observed even with health insurance coverage. Future research should investigate potential interventions to provide optimal and affordable care to at-risk patients and prevent long-term adverse financial outcomes in this vulnerable group.
Keywords: Financial hardship; chronic GVHD; hematopoietic cell transplantation.
Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Impact of Chronic Graft-versus-Host Disease on Patient Employment, Income, and Informal Caregiver Burden: Findings From the Living With Chronic GVHD Patient Survey.Transplant Cell Ther. 2023 Jul;29(7):470.e1-470.e9. doi: 10.1016/j.jtct.2023.04.004. Epub 2023 Apr 8. Transplant Cell Ther. 2023. PMID: 37037267
-
Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.Biol Blood Marrow Transplant. 2018 Feb;24(2):393-399. doi: 10.1016/j.bbmt.2017.10.009. Epub 2017 Oct 12. Biol Blood Marrow Transplant. 2018. PMID: 29032275 Free PMC article.
-
Financial burden in recipients of allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant. 2014 Sep;20(9):1375-81. doi: 10.1016/j.bbmt.2014.05.011. Epub 2014 May 24. Biol Blood Marrow Transplant. 2014. PMID: 24867778
-
Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead.Curr Hematol Malig Rep. 2015 Sep;10(3):183-91. doi: 10.1007/s11899-015-0265-2. Curr Hematol Malig Rep. 2015. PMID: 26303672 Review.
-
Quality of life and recovery after graft-versus-host disease.Best Pract Res Clin Haematol. 2008 Jun;21(2):333-41. doi: 10.1016/j.beha.2008.03.002. Best Pract Res Clin Haematol. 2008. PMID: 18503996 Review.
Cited by
-
A Vignette Study to Derive Health-Related Quality-of-Life Weights for Individuals with Steroid Refractory Chronic Graft-versus-Host Disease Receiving Third-Line Therapy in the United Kingdom.J Health Econ Outcomes Res. 2025 Feb 19;12(1):58-65. doi: 10.36469/001c.125546. eCollection 2025. J Health Econ Outcomes Res. 2025. PMID: 39991079 Free PMC article.
-
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes.Transplant Cell Ther. 2025 Apr;31(4):224.e1-224.e13. doi: 10.1016/j.jtct.2024.12.019. Epub 2024 Dec 27. Transplant Cell Ther. 2025. PMID: 39733839
-
Financial Hardship in Childhood Cancer Survivors Treated with Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study.Transplant Cell Ther. 2023 Nov;29(11):705.e1-705.e9. doi: 10.1016/j.jtct.2023.07.024. Epub 2023 Aug 2. Transplant Cell Ther. 2023. PMID: 37541329 Free PMC article.
-
Chronic graft-versus-host disease: unresolved complication or ancient history?Blood. 2024 Sep 26;144(13):1363-1373. doi: 10.1182/blood.2023022735. Blood. 2024. PMID: 39008818 Review.
-
Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada.EJHaem. 2020 Jul 10;1(1):69-78. doi: 10.1002/jha2.62. eCollection 2020 Jul. EJHaem. 2020. PMID: 35847696 Free PMC article.
References
-
- Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, Chubak J. Cancer survivors’ experiences with insurance, finances, and employment: results from a multisite study. Journal of cancer survivorship : research and practice. 2016. - PubMed
-
- Khera N, Chang YH, Hashmi S, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014;20:1375–1381. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources